GPR35 is a top genetically-associated target in inflammatory bowel diseases, including ulcerative colitis. GPR35 is expressed in epithelial cells and myeloid cells of the gastro-intestinal tract. Analysis has shown that GPR35 activation causes epithelial dysfunction and damage in colitis.
Our Science
A novel, transformative approach for patients with ulcerative colitis
We are developing oral, small molecule GPR35 inhibitors
GPR35 inhibitor
By inhibiting GPR35, ThirtyFiveBio are targeting the resolution of underlying disease causality and dysfunction in the gut epithelium.
Patient-led
Our science is founded on the importance of understanding human biology, with a focus on patient data and patient-derived cell and tissue models.
GPR35 inhibition protects gut epithelial cells under attack by inflammatory factors in colitis
Target
ThirtyFiveBio’s drug targets and binds to the GPR35 protein on the surface of gut epithelial cells.
Inhibit
Our antagonist potently inhibits the epithelial GPR35 receptor, preventing harmful signalling in the gut lining.
Shield
This inhibition protects the gut epithelium from damage, reducing inflammation and preventing UC flare-ups or disease progression.
GPR35 inhibition: An epithelial shield
Genetically-validated target
with unique understanding of role in disease.
Prevent underlying gut epithelial damage
in colitis, improving poor patient outcomes.
Monotherapy and combination potential
with various anti-inflammatory agents.
Preclinical development candidate selected
including filed patent portfolio.
Unlocking the power of GPR35 inhibition
GPR35 inhibition shows the promise of a backbone, orthogonal to anti-inflammatory approach that will improve disease resolution rates by resolving underlying epithelial damage in the gut barrier.
Current progress
ThirtyFiveBio have developed a preclinical development candidate small molecule inhibitor of GPR35.
What's next
We are advancing through late preclinical activities towards clinical proof-of-mechanism in 2028.
